ABSTRACT
Objective:To investigate the effect of somatostatin on portal vein diameter and biochemical parameters in decompensated cirrhosis with upper gastrointestinal bleeding.Methods:From January 2018 to January 2019, 90 patients with decompensated cirrhosis complicated with upper gastrointestinal bleeding admitted to the gastroenterology department of the Second People's Hospital of Changzhi were selected, and they were divided into two groups according to the random digital table method.The control group(45 cases)was treated with pantoprazole + thrombin, and the observation group(45 cases)was treated with somatostatin on the basis of the control group.The two groups were compared in terms of efficacy, portal vein diameter before and after treatment, biochemical indicators[interleukin-6(IL-6), hypersensitive C-reactive protein(hs-CRP), and procalcitonin(PCT)].Results:The effective rate of the observation group was higher than that of the control group(82.22% vs.62.22%), the difference was statistically significant(χ 2=4.486, P<0.05). After treatment, the anterior and posterior diameter of portal vein in the observation group[(1.12±0.23)cm] was significantly shorter than that in the control group[(1.22±0.22)cm], the difference was statistically significant( t=2.107, P<0.05). The serum levels of IL-6, hs-CRP and PCT were significantly decreased in both two groups after treatment(all P<0.05). The serum levels of IL-6, hs-CRP and PCT in the observation group were(10.32±3.69)ng/L, (13.35±5.46)mg/L, (5.26±1.47)μg/L, which were significantly lower than those in the control group [(15.32±5.69)ng/L, (19.35±7.51)mg/L, (9.45±3.02)μg/L], the differences were statistically significant( t=6.807, 8.433, 10.566, all P<0.05). Conclusion:Somatostatin is effective in the treatment of decompensated cirrhosis with upper gastrointestinal bleeding, which can reduce portal vein dilatation and serum inflammatory factor levels.Somatostatin is effective in the treatment of decompensated cirrhosis with upper gastrointestinal bleeding, which can reduce portal vein dilatation and serum inflammatory factor levels.
ABSTRACT
Objective:To study the mechanism of interleukin-10(IL-10)inhibiting the function of dendritic cells(DCs).Meth-ods:Cultured C57BL/6 mouse bone marrow-derived DCs were divided into 5 groups:control group,LPS stimulated group,IL-10 treated group,IL-10+Rapamycin treated group and Rapamycin treated group .The regulatory mechanism of IL-10 on dendritic cells were evalua-ted from DCs function ,Flow cytometry was used to analyse the expression of DCs surface co-stimulator CD80 ,CD40 expression ,the abil-ity of uptaking antigen and stimulating T cell to proliferate;ELISA was used to detect the cytokines IL-6 and TNF-α.Western blot was used to analyse the autophagy related protein LC3.Compared the differences between the groups.Results:(1)Compared to LPS stimu-lated group,IL-10 treated group,DCs surface co-stimulator CD40,CD80 were decreased,IL-6 and TNF-αsecretion level and the ability to stimulate T cell to proliferate were decreased ,the ability to capture OVA antigen was increased .Compared to IL-10 treated group ,the DCs surface co-stimulator CD80 was decreased ( P<0.05 ) ,IL-6 and TNF-αsecretion level and the ability to stimulate T cell to prolifer-ate were increased(P<0.0001)in IL-10+rapamycin treated group.In addition,autophagy related proteins LC3Ⅱ/LC3Ⅰwas decreased in IL-10 treated group.Conclusion:IL-10 may regulate functions of DCs through inhibiting the autophagy of DCs .
ABSTRACT
[Summary] A total of 128 individuals with type 2 diabetes underwent continuous glucose monitoring for 3 consecutive days.The dawn phenomenon was defined by three different parameters according to the previous research:(1)the absolute increase of glucose level from nocturnal nadir to prebreakfast value(?G) above 20 mg/dl;(2)?G above 10 mg/dl;( 3 ) insulin requirement increased at least 20%.The participants were secondarily separated by presence/absence of a dawn phenomenon based on the definitions above.The impact on blood glucose fluctuation of different groups was assessed according to the standard deviation of blood glucose( SDBG) , the area under curve above 10 mmol/L ( AUC ) , and the mean amplitude of glycemic excursions ( MAGE ) , etc.The frequencies of dawn phenomenon were 64.8%(?G≥20mg/dl), 85.2%(?G≥10 mg/dl), and 59.4%(rise in insulin requirement≥20%)respectively.The impacts on SDBG, AUC, MAGE, and MODD were without statistical difference(P>0.05) between the presence and absence of the dawn phenomenon patients when?G≥10 mg/dl.However, the differences reached statistical significance(P<0.05) when ?G≥20 mg/dl and the increase in insulin requirement≥20%. Besides, the incidence of dawn phenomenon was positively correlated with HOMA-IR, HbA1C , and free C-peptide.Dawn phenomenon is a very frequent event in type 2 diabetes and not only impacts the overall glycemic control but also exaggerates glucose fluctuation.To be clinically relevant, ?G≥20mg/dl should be taken as the quantitative criterion of the dawn phenomenon.